CSIMarket
 
Biolinerx Ltd   (BLRX)
 
Price: $2.5850 $0.02 0.584%
Day's High: $2.619999885559082 Week Perf: -3.18 %
Day's Low: $ 2.55 30 Day Perf: -3.9 %
Volume (M): 3,216 52 Wk High: $ 4.56
Volume (M$): $ 0 52 Wk Avg: $3.05
Open: $2.58 52 Wk Low: $2.15



 Market Capitalization (Millions $) 6,373
 Shares Outstanding (Millions) 2,465
 Employees 24
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


BioLineRx Ltd is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for a wide range of diseases. The company was founded in 2003 and is headquartered in Modi'in, Israel. BioLineRx operates globally with offices in the United States, Europe, and Asia, and is listed on the NASDAQ and Tel Aviv Stock Exchanges.

BioLineRx's focus is on the development of novel, therapeutics for oncology, immunology, and other disease areas, with a particular focus on drugs that target unmet medical needs, including rare and hard-to-treat diseases. The company's pipeline consists of both in-house development programs and collaborations with other leading pharmaceutical and biotech companies.

BioLineRx's lead product candidate, BL-8040, is a novel cancer therapy that targets both cancer stem cells and the tumor microenvironment. It is currently being evaluated in multiple clinical trials for hematological malignancies and solid tumors. The company's other pipeline candidates include novel immunotherapies, gene therapies, and small molecules targeting various cancers, inflammatory and autoimmune diseases, and infectious diseases.

BioLineRx is also actively engaged in collaborations with other leading pharmaceutical and biotech companies, including Novartis, Genentech, Merck, and Roche. These collaborations leverage BioLineRx's expertise in drug discovery and development to advance promising therapeutics through clinical trials and regulatory approval.

The company is committed to leveraging cutting-edge technologies in its drug development programs, including genomics, proteomics, and computational biology. BioLineRx has a strong intellectual property portfolio, with more than 60 patents and patent"},"finish


   Company Address: 2 HaMa’ayan Street Modi’in 7177871
   Company Phone Number: 642-9100   Stock Exchange / Ticker: BLRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
HCM   -9.21%    
IRWD   -7.58%    
JAGX   -56.63%    
RDHL   -8.49%    
REGN   -7.13%    
VRTX   -8.07%    
• View Complete Report
   





Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4,294.29
Price to Sales (Expected) -
Price to Book 272.98
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.27
Working Capital Ratio 1.95
Leverage Ratio (MRQ) 0.75
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) 0 $
Cash Flow (TTM) -
Cash 0 $
Book Value 0.01 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 61,833
Net Income per Employee (TTM) -248,583
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.04

Profitability Ratios Current
Gross Margin (MRQ) 80.51 %
Operating Margin (MRQ) -871.78 %
Net Margin (MRQ) -171.69 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Biolinerx Ltd's Segments
U S    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.